* – This article has been archived and is no longer updated by our editorial team –
Below is our recent interview with Brianna Wronko, CEO at Group K Diagnostics:
Q: For those who have never heard of it, how would you describe Group K Diagnostics?
A: Our vision at Group K Diagnostics is to radically improve patient care by reducing the time and cost to receive accurate laboratory diagnostics, as well as ease the burden on the provider by producing a test strip and complete software platform. We deliver diagnostic results within 20 minutes.
Q: What is your core competence?
A: Our core competency is delivering very accurate tests to markets that are in high need of rapid results.
Q: How do people usually become aware of your company?
A: People usually become aware of us through news articles or by searching for a solution to their problem of timely diagnostics.
Q: You’ve recently managed to raise $2M, could you tell us more about your recent funding round?
The growth and expansion enabled by this investment brings our team closer to making our mission a reality – providing reliable, affordable test results to patients, and giving providers the opportunity to take immediate therapeutic action based on those results.
The operations efficiencies our team has been able to achieve will ensure that every penny of this funding will be used in a meaningful, productive manner that helps to bring our technology closer to fruition. We believe the diagnostics tool we intend to bring to market will help to shift the healthcare system from a largely responsive care model to preventative – and we’re grateful to the investors who are helping to make that a reality.
Q: What can we expect from your company in the next six months?
A: In the next few months, we will be completing our liver function clinical trial, beginning a comprehensive metabolic clinical trial and moving into an expanded new lab and manufacturing space.